Compare SNY & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNY | REGN |
|---|---|---|
| Founded | 1994 | 1988 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.7B | 84.3B |
| IPO Year | 2001 | 1995 |
| Metric | SNY | REGN |
|---|---|---|
| Price | $46.64 | $919.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 28 |
| Target Price | $54.92 | ★ $991.00 |
| AVG Volume (30 Days) | ★ 4.2M | 869.8K |
| Earning Date | 10-30-2026 | 10-30-2026 |
| Dividend Yield | ★ 5.25% | 0.41% |
| EPS Growth | N/A | ★ 8.19 |
| EPS | N/A | ★ 37.37 |
| Revenue | N/A | ★ $5,872,227,000.00 |
| Revenue This Year | $3.97 | $31.18 |
| Revenue Next Year | $6.77 | $7.19 |
| P/E Ratio | ★ $6.14 | $24.71 |
| Revenue Growth | N/A | ★ 20.82 |
| 52 Week Low | $39.07 | $591.52 |
| 52 Week High | $50.61 | $991.73 |
| Indicator | SNY | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 57.70 | 57.41 |
| Support Level | $45.95 | $735.26 |
| Resistance Level | $48.57 | $986.64 |
| Average True Range (ATR) | 0.86 | 32.57 |
| MACD | -0.20 | -4.43 |
| Stochastic Oscillator | 40.49 | 32.58 |
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.